• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration

    Thumbnail
    View/ Open
    WJG-22-4732.pdf (1.045Mb)

    Show full item record
    
    Author
    Hunt, Christine M.; Beste, Lauren A.; Lowy, Elliott; Suzuki, Ayako; Moylan, Cynthia A.; Tillmann, Hans L.; Ioannou, George N.; Lim, Joseph K.; Kelley, Michael J.; Provenzale, Dawn
    Abstract
    AIM: To evaluate pretreatment hepatitis B virus (HBV) testing, vaccination, and antiviral treatment rates in Veterans Affairs patients receiving anti-CD20 Ab for quality improvement. METHODS: We performed a retrospective cohort study using a national repository of Veterans Health Administration (VHA) electronic health record data. We identified all patients receiving anti-CD20 Ab treatment (2002-2014). We ascertained patient demographics, laboratory results, HBV vaccination status (from vaccination records), pharmacy data, and vital status. The high risk period for HBV reactivation is during anti-CD20 Ab treatment and 12 mo follow up. Therefore, we analyzed those who were followed to death or for at least 12 mo after completing anti-CD20 Ab. Pretreatment serologic tests were used to categorize chronic HBV (hepatitis B surface antigen positive or HBsAg+), past HBV (HBsAg-, hepatitis B core antibody positive or HBcAb+), resolved HBV (HBsAg-, HBcAb+, hepatitis B surface antibody positive or HBsAb+), likely prior vaccination (isolated HBsAb+), HBV negative (HBsAg-, HBcAb-), or unknown. Acute hepatitis B was defined by the appearance of HBsAg+ in the high risk period in patients who were pretreatment HBV negative. We assessed HBV antiviral treatment and the incidence of hepatitis, liver failure, and death during the high risk period. Cumulative hepatitis, liver failure, and death after anti-CD20 Ab initiation were compared by HBV disease categories and differences compared using the χ2 test. Mean time to hepatitis peak alanine aminotransferase, liver failure, and death relative to anti-CD20 Ab administration and follow-up were also compared by HBV disease group. RESULTS: Among 19304 VHA patients who received anti-CD20 Ab, 10224 (53%) had pretreatment HBsAg testing during the study period, with 49% and 43% tested for HBsAg and HBcAb, respectively within 6 mo pretreatment in 2014. Of those tested, 2% (167/10224) had chronic HBV, 4% (326/7903) past HBV, 5% (427/8110) resolved HBV, 8% (628/8110) likely prior HBV vaccination, and 76% (6022/7903) were HBV negative. In those with chronic HBV infection, ≤ 37% received HBV antiviral treatment during the high risk period while 21% to 23% of those with past or resolved HBV, respectively, received HBV antiviral treatment. During and 12 mo after anti-CD20 Ab, the rate of hepatitis was significantly greater in those HBV positive vs negative (P = 0.001). The mortality rate was 35%-40% in chronic or past hepatitis B and 26%-31% in hepatitis B negative. In those pretreatment HBV negative, 16 (0.3%) developed acute hepatitis B of 4947 tested during anti-CD20Ab treatment and follow-up. CONCLUSION: While HBV testing of Veterans has increased prior to anti-CD20 Ab, few HBV+ patients received HBV antivirals, suggesting electronic health record algorithms may enhance health outcomes.
    URI
    http://hdl.handle.net/10342/8032
    Subject
    Hepatitis B, Hepatitis B reactivation, Anti-CD20 antibody, Rituximab, Lymphoma, Chemotherapy, Hepatitis B antivirals, Vaccination, Veteran
    Date
    2016-05-21
    Citation:
    APA:
    Hunt, Christine M., & Beste, Lauren A., & Lowy, Elliott, & Suzuki, Ayako, & Moylan, Cynthia A., & Tillmann, Hans L., & Ioannou, George N., & Lim, Joseph K., & Kelley, Michael J., & Provenzale, Dawn. (May 2016). Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World Journal of Gastroenterology, (22:19), p.. Retrieved from http://hdl.handle.net/10342/8032

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Hunt, Christine M., and Beste, Lauren A., and Lowy, Elliott, and Suzuki, Ayako, and Moylan, Cynthia A., and Tillmann, Hans L., and Ioannou, George N., and Lim, Joseph K., and Kelley, Michael J., and Provenzale, Dawn. "Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration". World Journal of Gastroenterology. 22:19. (.), May 2016. August 15, 2022. http://hdl.handle.net/10342/8032.
    Chicago:
    Hunt, Christine M. and Beste, Lauren A. and Lowy, Elliott and Suzuki, Ayako and Moylan, Cynthia A. and Tillmann, Hans L. and Ioannou, George N. and Lim, Joseph K. and Kelley, Michael J. and Provenzale, Dawn, "Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration," World Journal of Gastroenterology 22, no. 19 (May 2016), http://hdl.handle.net/10342/8032 (accessed August 15, 2022).
    AMA:
    Hunt, Christine M., Beste, Lauren A., Lowy, Elliott, Suzuki, Ayako, Moylan, Cynthia A., Tillmann, Hans L., Ioannou, George N., Lim, Joseph K., Kelley, Michael J., Provenzale, Dawn. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World Journal of Gastroenterology. May 2016; 22(19) . http://hdl.handle.net/10342/8032. Accessed August 15, 2022.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback